Inflammatory bowel disease is a group of medical indication that causes chronic inflammation in the gastrointestinal tract. The inflammatory bowel disease mainly comprises of Ulcerative colitis and Crohn’s disease. The ulcerative colitis primarily affects the large intestine and anus and it causes the inflammation sores in the inner lining of colon and rectum. The Crohn’s disease affects any part of gastrointestinal tract and unlike ulcerative colitis, it affects all the layers of gastrointestinal walls. The ulcerative colitis is more prevalent than that of Crohn’s disease. The IBD affects equally in men and women and has prevalence and incidence rates in developed countries than that of developing and under developed countries. The exact cause of inflammatory bowel disease are not well understood however, the combination of several factors such as autoimmune disorders, genetic factors, lifestyle related risks factors such as smoking, sedentary lifestyle, lack of exercise are likely to contribute to the development of symptoms of inflammatory bowel disease. The common symptoms of inflammatory bowel disease includes the severe abdominal cramps and pain, persistent diarrhea, occasional rectal bleeding.
The IBD has no permanent cure and requires the lifelong disease management and treatment. Several medications such as corticosteroids, aminosalicyclates, immunomodulators, and biologic drugs such as TNF inhibitors and up to certain extent antibiotic drugs are prescribed to relive the symptoms of these diseases.

Market Analysis and Insights: Global Inflammatory Bowel Disease (IBD) Treatment Market
The global Inflammatory Bowel Disease (IBD) Treatment market size is projected to reach US$ 15660 million by 2027, from US$ 13310 million in 2020, at a CAGR of 2.3% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Inflammatory Bowel Disease (IBD) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Inflammatory Bowel Disease (IBD) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Inflammatory Bowel Disease (IBD) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Inflammatory Bowel Disease (IBD) Treatment market.

Global Inflammatory Bowel Disease (IBD) Treatment Scope and Market Size
Inflammatory Bowel Disease (IBD) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Inflammatory Bowel Disease (IBD) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
TNF Inhibitors
Aminosalicyclates
Immunomodulators
Corticosteroids

Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AbbVie
Pfizer
Takeda
Janssen Biotech
Allergan
Bausch Health
Takeda Pharmaceutical
Novartis
Biogen